FSNUF — Fresenius SE & Co. KGaA

OTC · Health Care · Health Care Equipment & Supplies · CIK 904868 ·
Last close
$54.35
Market Cap
$30.61B
52W High
$54.35
52W Low
$53.13
ADV30
0
Next earnings
2026-08-05
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 5,818,000,000 1,534,000,000 601,000,000 435,000,000 42,370,000,000 2,059,000,000 21,905,000,000
Dec 2025 6,156,000,000 1,524,000,000 468,400,000 361,000,000 41,395,000,000 1,307,000,000 21,628,000,000
Jun 2025 5,581,000,000 1,458,000,000 560,000,000 330,000,000 41,320,000,000 1,226,000,000 22,378,000,000
Mar 2025 5,651,000,000 1,411,000,000 687,000,000 229,000,000 43,207,000,000 2,387,000,000 23,137,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$2,776,000,000
Investing CF
$-884,000,000
Financing CF
$-2,926,000,000
CapEx
$-1,491,000,000
Dividends Paid
$-656,000,000
Buybacks
EPS Diluted TTM
$1.57
As of
2026-05-10

Yahoo Snapshot (yfinance, live)

Total Revenue
$22,986,000,384
EBITDA
$3,033,400,064
Free Cash Flow
$1,804,749,952
Enterprise Value
$41,139,945,472
Total Cash
$2,059,000,064
Total Debt
$11,905,000,448
Shares Out
563,237,277
Trailing EPS
$3.11
Book Value
$40.47
ROE
7.8%
ROA
3.3%
Div Yield
2.25%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 22,873,000,000 2,181,400,000 1,264,000,000 41,395,000,000 21,628,000,000 2,574,000,000
Dec 2024 21,954,000,000 2,073,000,000 471,000,000 43,550,000,000 23,260,000,000 2,447,000,000
Dec 2023 21,067,000,000 1,183,000,000 -594,000,000 45,284,000,000 25,633,000,000 4,456,000,000
Dec 2022 21,532,000,000 1,812,000,000 1,372,000,000 76,400,000,000 44,182,000,000 4,198,000,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$3.52

Peers — same industry

TickerNameMarket CapLastDaily %
MDLN Medline Inc. $30.45B $36.01
DXCM DEXCOM INC $30.17B $78.19
GEHC GE HealthCare Technologies Inc. $30.03B $66.01
RMD RESMED INC $28.57B $196.94
PHG KONINKLIJKE PHILIPS NV $25.76B $26.50

News headlines (Yahoo Finance, 1h cache)

Fresenius (FMS) Q1 2026 Earnings Transcript
2026-06-01 21:28 · Yahoo
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
2026-05-29 13:40 · Yahoo
Late-Stage Chronic Kidney Disease Market Analysis Report 2026-2036, Profiles of Key Players - Novartis, Merck & Co, Pfizer, Sanofi, and Johnson & Johnson
2026-05-21 13:21 · Yahoo
Should Value Investors Buy Fresenius SE & Co. (FSNUY) Stock?
2026-05-13 13:40 · Yahoo
How The Fresenius SE KGaA (XTRA:FRE) Investment Story Is Evolving With Mixed Analyst Targets
2026-04-23 19:07 · Yahoo
Quest Diagnostics Q1 Earnings Call Highlights
2026-04-21 14:45 · Yahoo
CMS Grants Fresenius Kabi COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg)
2026-04-09 12:00 · Yahoo
Fresenius Medical Care AG (FMS) Looks to Improve Profitability After Smashing Q4 Expectations
2026-03-13 18:31 · Yahoo
Here's Why Fresenius (FMS) is a Strong Value Stock
2026-03-05 14:40 · Yahoo
Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary
2026-02-27 13:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.